Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Symptoms and General Pathology

Infections

Heart and Blood Diseases

Rare Diseases

Prediabetic State

Kidney Diseases

Lung Diseases, Obstructive

Pulmonary Disease, Chronic Obstructive

COVID-19

Heart Failure

Atrial Fibrillation

Urolithiasis

Coronary Artery Disease

Myocardial Ischemia

Hypertension

Heart Diseases

Glucose Intolerance

Ischemia

Lung Diseases

Urinary Calculi

Albuminuria

Renal Insufficiency, Chronic

Renal Insufficiency

Coronary Disease

Vascular Diseases

Arrhythmias, Cardiac

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Respiratory Tract Diseases

Chronic Disease

Disease Attributes

Arteriosclerosis

Arterial Occlusive Diseases

Proteinuria

Urination Disorders

Urological Manifestations

Chronic Graft Versus Host Disease

Patients aged 40 or older without preexisting diagnoses of chronic kidney disease, type 1 diabetes, and type 2 diabetes with positive albuminuria by dipsticks and/or microalbuminuria test or albumin-to-creatinine ratio in a single urine sample.

Elena Semenova, PhD

Alexander Vaskin

Alexander Arutyunov, professor

Real clinical practice register of Albuminuria detection in patients with previously undiagnosed chronic kidney disease

This register was sponsored and organized by the Association "Eurasian Association of Internal Medicine". It is a multicenter non-interventional register of real clinical practice. The database will include patients aged 40 years and older without pre-existing nephrological disease who are available for a dipstick test for albuminuria. The subjects will be identified by screening all patients who meet inclusion/exclusion criteria during routine outpatient and hospital follow-up. The register does not include follow-up (cross-sectional design).

Patients eligible for the register should be enrolled and documented. The procedure for obtaining informed consent for the collection and analysis of the retrospective data must comply with the local legislation. If necessary, patients will be asked to sign an informed consent document.

All study sites will use standardized electronic CRFs. The Electronic Data Capture (EDC) system should be validated in accordance with current standards and legal requirements. The investigators will log into this system using individual usernames and passwords. Data may only be entered and corrected by the investigator or other authorized study site personnel.

Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease

Eurasian Association of Therapists

Neoplasms

Neoplasm Metastasis

Kidney Calculi

Nephrolithiasis

Hyperoxaluria

Calculi

Neoplastic Processes

Pathological Conditions, Anatomical

Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.

Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period

Lanthanum Carbonate

Celine Olbrechts, Study Coordinator

Els Van de Perre, MD

Celine Olbrechts

Christian Tielemans, MD, PhD

This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.

Nephrolithiasis/urolithiasis is a prevalent (overall lifetime risk up to 13% in Western countries) and highly recurrent disease. Secondary hyperoxaluria is a key risk factor for the development of calcium oxalate stones, the most frequent stone type. Currently used therapeutic options in secondary hyperoxaluria have limited efficacy. Recent findings in vitro and in a rat model, provided evidence that Lanthanum Carbonate is an effective oxalate binder. The objective of this study is to investigate whether treatment with Lanthanum Carbonate reduces urinary oxalate excretion in human subjects with secondary hyperoxaluria and nephrolithiasis. By treating the patients with two different doses of Lanthanum Carbonate during two 14-day treatment periods, a dose-response will be evaluated.

This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis. Patients will be treated during 2 consecutive 14-day treatment periods with a low and a high dose of Lanthanum Carbonate respectively.

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis: a Short-term, Prospective, Open-label, Efficacy and Safety Clinical Trial

Mean reduction in urinary oxalate excretion after the first 14-day treatment period during which patients will be treated with 250 mg Lanthanum Carbonate 3x/day with meals, expressed in mg oxalate/g creatinine.

Incremental reduction of mean urinary oxalate excretion after the second 14-day treatment period during which the patients will be treated with 500 mg Lanthanum Carbonate 3x/day with meals, expressed in mg oxalate/g creatinine

Severe hypophosphatemia is defined as serum phosphorus \< 0.64 mmol/L

24-hour urinary phosphorus excretion will be expressed in mmol/24 hours

Urinary phosphorus to creatinine ratio will be expressed in mmol phosphorus/g creatinine

Fractional excretion of phosphorus will be expressed in %, defined as (urinary phosphorus (mmol/L) x serum creatinine (mg/dL) / (serum phosphorus (mmol/L) x urine creatinine (mg/dL))

Hypophosphaturia is defined as urinary phosphorus \< 12.9 mmol/24 hours

24-hour urinary calcium excretion will be expressed in mmol/24 hours

Urinary calcium to creatinine ratio will be expressed in mmol calcium/g creatinine

Fractional excretion of calcium will be expressed in %, defined as (urinary calcium (mmol/L) x serum creatinine (mg/dL)) / (serum calcium (mmol/L) x urine creatinine (mg/dL))

Serum Lanthanum levels will be expressed in mcg/L

The number and the proportion of patients experiencing adverse events

Universitair Ziekenhuis Brussel

Nervous System Diseases

Hemorrhage

Lung Neoplasms

Necrosis

Pain

Flank Pain

Intracranial Hemorrhages

Neurologic Manifestations

Cerebrovascular Disorders

Brain Diseases

Central Nervous System Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

CNS: Known or suspected pathology in the posterior fossa

Thorax: Patients referred for staging of a known or suspected lung cancer

Abdomen: Patients with acute flank pain and suspected urolithiasis

Abdomen: Patients with a known or suspected focal liver lesion

This study is being performed to confirm that the new technique, Model-Based Iterative Reconstruction (MBIR) with reduced radiation dose can deliver equivalent image quality for CT scans compared to current techniques (Filtered Back Projection with Adaptive Statistical Iterative Reconstruction (FBP with ASiR) and also to demonstrate that MBIR can improve general image quality characteristics at equivalent radiation dose levels.

Pilot Study of Model Based Iterative Reconstruction Using 64-Slice

Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen

Ultra-low radiation dose images reconstructed with MBIR yield similar anatomic and pathologic information compared to routine radiation dose images reconstructed with Filtered Back Projection (FBP) in the central nervous system (CNS), thorax, and abdomen.

American College of Radiology - Image Metrix

GE Healthcare

Urinary Bladder Neoplasms

Urinary Bladder Neck Obstruction

Urinary Bladder Diseases

Urethral Obstruction

Urethral Diseases

Members of healthcare teams involved in the delivery of day-case endourology operations.

These are qualitative interviews and involve no intervention

None - qualitative interviews

Joseph B John, BSc, MBBS

John S McGrath, MBBS, MD

A qualitative research study conducted in hospitals across England, in which staff members will be interviewed. We will interview staff who are directly or indirectly involved in delivering care for patients undergoing the operations of interest; namely bladder tumour resection, prostate resection or enucleation, and ureteroscopy for upper urinary tract stones. We hope to find out the reasons why some hospitals can perform day-case surgery with very high rates, and why others do not. We also hope to find out about any unexpected outcomes observed when performing day-case surgery for the operations of interest.

Staff working in a range of different hospitals from across England with varying day-case rates will be interviewed. Hospitals in large city and more rural areas will be assessed. Interviews are anticipated to take place over a six month period. The study will end when "saturation" is achieved, whereby no new themes are identified through interviews. Saturation will be sought for each individual operation of interest.

Safe day-case surgery pathways offer to reduce pressure on hospitals by avoiding overnight inpatient admission. This is particularly relevant given the intense pressures on hospital resources in the United Kingdom. Urological surgery includes a number of frequently performed operations for which safe day-case surgery pathways have been demonstrated. These include bladder tumour resection (TURBT), prostate resection or enucleation using diathermy or laser (TURP and TUEP), and ureteroscopy and laser for upper urinary tract stones (URS). All of these operation types involve endoscopic access to the bladder via the urethra, and do not involve skin incisions. They can be performed under general or spinal anaesthesia, although spinal anaesthesia is rarely used for ureteroscopy.

For the 12 months from December 2021, the national median day-case rate for transurethral resection of bladder tumour In England was 21.1%, and ranged from 0% to 87.3% at different hospitals, with an interquartile range (IQR) of 10.5% to 37.7%, and 23,071 cases performed in total. For bladder outflow obstruction surgery the median day-case rate was 7.7% (range 0% to 82.4%, IQR 4.4% to 19.1%, 18,912 cases), and this includes TURP and TUEP. For URS the median day case rate was 60.1% (range 0% to 87.9%, IQR 44.4% to 69.7%, 23,130 cases). This demonstrates that for these common operations there is significant variation in practice across England.

The Getting It Right First Time (GIRFT) Urology programme advocates for a "day-case by default" approach to TURBT and URS, and that day-case surgery should ideally be offered for prostate resection and enucleation. As well as reducing pressure on inpatient services, greater day-case adoption offers to reduce financial costs, shorten waiting lists by allowing greater access to day-case theatres away from the acute hospital, and reduce environmental impact by adopting a less resource-intensive approach. It also offers a more standardised patient experience.

National day-case rates for all of TURBT, TURP/TUEP and URS have increased over the past five years, however the wide variation in practice identifies a need to understand reasons underlying a significant observed divergence in practice. We want to understand why some hospitals have rapidly adopted day-case surgery whereas others have not. Furthermore, it is necessary to understand any positive and negative outcomes associated with the increased utilisation of day-case surgery. In order to explore this area we intend to perform qualitative research involving members of staff involved in the delivery of one or more of the operations of interest. We will interview staff from a range of different hospitals with differing day-case performances to further understand enablers and barriers associated with day-case adoption. We would also like to understand staff members' experiences of any wider unexpected outcomes associated with day-case surgery adoption.

Day-case Endourology; Enablers, Barriers, Unexpected Outcomes

Understanding Enablers, Barriers, and Unexpected Outcomes Associated With Adoption of Routine Day-case Surgery Pathways for Common Endourology Operations: Qualitative Interviews With Healthcare Professionals.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease	NCT05690009	Chronic Kidney ... Hypertension Chronic Heart F... Ischemic Heart ... Atrial Fibrilla... PreDiabetes Chronic Obstruc... Cancer Urolithiasis COVID-19		40 Years -	Eurasian Association of Therapists
Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis	NCT03346369	Secondary Hyper... Nephrolithiasis	Lanthanum Carbo...	18 Years -	Universitair Ziekenhuis Brussel
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice	NCT01431378	Posterior Fossa... Lung Cancer Flank Pain Urolithiasis Focal Hepatic N...		30 Years -	GE Healthcare
Day-case Endourology; Enablers, Barriers, Unexpected Outcomes	NCT06152666	Bladder Cancer Bladder Outlet ... Urolithiasis	None - qualitat...	-	Royal Devon and Exeter NHS Foundation Trust

Spots Global Cancer Trial Database for urolithiasis

Every month we try and update this database with for urolithiasis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.